Advanced search
Publication Cover
International Journal of Neuroscience Volume 126, 2016 - Issue 11
Submit an article Journal homepage
357
Views
16
CrossRef citations to date
0
Altmetric
Original Articles

Effect of bevacizumab on intracranial meningiomas in patients with neurofibromatosis type 2 – a retrospective case series

Mikkel Christian AlaninDepartment of Otolaryngology – Head and Neck Surgery and Audiology, Copenhagen University Hospital, Copenhagen, DenmarkCorrespondence[email protected]
,
Camilla KlausenDepartment of Radiology, Copenhagen University Hospital, Copenhagen, Denmark
,
Per Caye-ThomasenDepartment of Otolaryngology – Head and Neck Surgery and Audiology, Copenhagen University Hospital, Copenhagen, Denmark;Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
,
Carsten ThomsenDepartment of Radiology, Copenhagen University Hospital, Copenhagen, Denmark;Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
,
Kaare FugleholmDepartment of Neurosurgery, Copenhagen University Hospital, Copenhagen, Denmark
,
Lars PoulsgaardDepartment of Neurosurgery, Copenhagen University Hospital, Copenhagen, Denmark
,
Ulrik LassenDepartment of Oncology and Radiotherapy, Copenhagen University Hospital, Copenhagen, Denmark
,
Morten Mau-SorensenDepartment of Oncology and Radiotherapy, Copenhagen University Hospital, Copenhagen, Denmark
&
Kenneth Francis HoflandDepartment of Oncology and Radiotherapy, Copenhagen University Hospital, Copenhagen, Denmark
 show all
Pages 1002-1006 | Received 04 Jun 2015, Accepted 07 Sep 2015, Published online: 06 Oct 2015

References

  • Evans DG. Neurofibromatosis type 2 (NF2): a clinical and molecular review. Orphanet J Rare Dis 2009;4:16.
  • Sherman WJ, Raizer JJ. Chemotherapy: what is its role in meningioma? Expert Rev Neurother 2012;12:1189–95.
  • Rogers L, Barani I, Chamberlain M, et al. Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review. J Neurosurg 2015;122:4–23.
  • Plotkin SR, Stemmer-Rachamimov AO, Barker FG, et al. Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N Engl J Med 2009;361:358–67.
  • Nunes FP, Merker VL, Jennings D, et al. Bevacizumab treatment for meningiomas in NF2: a retrospective analysis of 15 patients. PLoS One 2013;8:e59941 (Epub ahead of print).
  • Alanin MC, Klausen C, Caye-Thomasen P, et al. The effect of bevacizumab on vestibular schwannoma tumour size and hearing in patients with neurofibromatosis type 2. Eur Arch Otorhinolaryngol 2014. doi:10.1007/s00405-014-3398-3
  • Lou E, Sumrall AL, Turner S, et al. Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series. J Neurooncol 2012;109:63–70.
  • Nayak L, Iwamoto FM, Rudnick JD, et al. Atypical and anaplastic meningiomas treated with bevacizumab. J Neurooncol 2012;109:187–93.
  • Evans DG, Huson SM, Donnai D, et al. A clinical study of type 2 neurofibromatosis. Q J Med 1992;84:603–18.
  • National Institutes of Health Consensus Development Conference Statement on Acoustic Neuroma, December 11–13, 1991. The Consensus Development Panel. Arch Neurol 1994;51:201–7.
  • Macdonald DR, Cascino TL, Schold SC, Jr., Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990;8:1277–80.
  • Hawasli AH, Rubin JB, Tran DD, et al. Antiangiogenic agents for nonmalignant brain tumors. J Neurol Surg B Skull Base 2013;74:136–41.
  • Goutagny S, Raymond E, Sterkers O, et al. Radiographic regression of cranial meningioma in a NF2 patient treated by bevacizumab. Ann Oncol 2011;22:990–1.
  • Zeidman LA, Ankenbrandt WJ, Du H, et al. Growth rate of non-operated meningiomas. J Neurol 2008;255:891–5.
  • Dombi E, Ardern-Holmes SL, Babovic-Vuksanovic D, et al. Recommendations for imaging tumor response in neurofibromatosis clinical trials. Neurology 2013;81:S33–40.
  • Plotkin SR, Merker VL, Halpin C, et al. Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients. Otol Neurootol 2012;33:1046–52.
  • Mautner VF, Nguyen R, Kutta H, et al. Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2. Neuro-Oncology 2010;12:14–8.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.